Xarelto Internal Bleeding
Risk of Severe Internal Bleeding and Hemorrhagic Stroke Linked to Xarelto
Xarelto (rivaroxaban) is an oral anti-coagulant which is used to prevent the formation of blood clots that can obstruct blood flow to the brain and other vital organs. Though initially to offer a safer, more convenient alternative to warfarin drugs, Xarelto is now known to cause severe and unstoppable internal bleeding and hemorrhagic stroke. Today, some doctors and researchers say the risks posed by Xarelto for internal bleeding and stroke likely outweigh the drug’s benefits. This page contains comprehensive information on the uses, risks, and dangers of Xarelto.
Xarelto Bleeding Risks
Xarelto was approved by the FDA through a fast-track regulatory review in 2011 for use in patients to prevent deep vein thrombosis following knee and hip replacement surgery, and to prevent stroke in patients with non-valvular atrial fibrillation.
When Xarelto was first released, it was seen as a more convenient and more effective blood thinner, among a new class of oral coagulants – alternatives to Coumadin (warfarin), which had been the standard anti-coagulant in use since the 1950s. Doctors embraced the new drug, and many patients quickly switched to Xarelto, glad to be relieved of regular dosage monitoring and dietary restrictions.
As with any blood-thinner, dangerous bleeding events and hemorrhagic stroke were a known risk from the start with Xarelto. In the ensuing years since receiving FDA approval, Xarelto internal bleeding deaths have far exceeded the drug maker’s estimates. The threat of hemorrhagic stroke and severe internal bleeding caused by Xarelto has been the subject of an FDA warning letter. The makers of Xarelto, Bayer and Janssen, were chastised for making false claims, both minimizing the risk of Xarelto bleeding and overstating the effectiveness of the drug.
Perhaps most alarming about the drug Xarelto is that no antidote has been found to stop Xarelto bleeding once it begins. Patients have been hospitalized, and have even died while under advanced medical care at a hospital, as a result of Xarelto bleeding. Once hemorrhaging or internal bleeding begins, doctors have no reliable method to halt it. This fact alone makes Xarelto more dangerous that warfarin drugs such as Coumadin, which can be quickly counteracted with Vitamin K.
How Xarelto Works
Xarelto has been approved to treat patients who suffer from atrial fibrillation, as well as patients in recovery following hip and knee replacement surgeries. The drug “thins the blood” to prevent dangerous blood clots from forming by inhibiting factor Xa, a naturally occurring enzyme in the blood that is essential to blood clotting functions.
Atrial fibrillation is a heart condition suffered by over 2 million Americans. Characterized by an irregular heartbeat that can result in a dangerous pooling of blood in the heart’s atria. When blood pools in the atria, blood clots may form. If a blood clot becomes lodged in the brain, it is known as an embolus and it causes disabling and potentially fatal embolic stroke. For this reason patients suffering from atrial fibrillation are seven times more likely to suffer from embolic stroke than other Americans of a similar demographic.
Patients who have undergone hip or knee replacement surgery have a high risk of stroke immediately following the surgery. For this reason, Xarelto and other blood thinners are commonly prescribed to patients following such a procedure. While Xarelto offers convenience over warfarin drugs, it is also quote expensive, costing patients approximately $3000.00 annually.
Xarelto Internal Bleeding and Hemorrhagic Stroke
Far from offering a safer, more effective alternative to Coumadin, Xarelto is now thought to be less effective and more dangerous than warfarin drugs. Post-market reports of Xarelto bleeding exposed a pair of serious issues with the drug. One was that the internal bleeding complications were taking place at a higher rate than had been projected in the fast-track regulatory approval process. The risk of bleeding problems is a concern with any blood thinner, but Xarelto bleeding deaths have been far more common than product warnings led consumers to expect.
The other issue that arose in relation to Xarelto was that the drug had no corrective measures to combat the bleeding complications it caused. The drug’s makers have failed to provide medical professionals with reliable instructions to stop Xarelto bleeding. For these problems, and for their failure to adequately warn patients of the risks associated with the drug, Bayer and Janssen Pharmaceuticals are now facing Xarelto internal bleeding & death lawsuits.
The risks and shortcoming of Xarelto were documented in a 2011 study known as the ROCKET-AF study, which compared warfarin and Xarelto in 14,000 patients suffering from atrial fibrillation. The study concluded that Xarelto is less effective at preventing stroke and embolism than warfarin. Additionally, serious bleeding events were more likely to occur in patients taking Xarelto.
Xarelto Bleeding Lawyers Offer Free Case Review
Our attorneys handling Xarelto bleeding lawsuits on behalf of individuals and their family members who suffered from severe internal bleeding or hemorrhagic stroke while taking Xarelto. They will work tirelessly on your behalf to assure you get the compensation you deserve. If you or a loved one suffered from severe internal bleeding or hemorrhagic stroke while taking Xarelto, a Xarelto bleeding attorney can help by answering your questions and giving you a sense of your legal options.
Xarelto Bleeding Lawsuits
Persons who suffered from or died as a result of severe bleeding or hemorrhage while taking Xarelto may have grounds for a Xarelto bleeding lawsuit. We provide legal representation for Xarelto lawsuits on a contingency basis, meaning that we never charge a fee unless we win compensation on your behalf.